6-amino-5-chloro-N-({1-[2-(2,4-dimethoxyphenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2-oxo-1,2-dihydropyridine-3-carboxamide | 557106-68-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-amino-5-chloro-N-({1-[2-(2,4-dimethoxyphenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
• 英文别名: 6-amino-5-chloro-N-[[1-[2-(2,4-dimethoxyphenyl)-2-oxoethyl]piperidin-4-yl]methyl]-2-oxo-1H-pyridine-3-carboxamide
• CAS: 557106-68-0
• 化学式: C₂₂H₂₇ClN₄O₅
• 分子量: 462.933
• InChiKey: UHUIJMCQVPBJJT-UHFFFAOYSA-N

物化性质

• 沸点：
  666.3±55.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
  申请人：——

  公开号：US20030207875A1

  公开（公告）日：2003-11-06

  This invention provides compounds of the formula (I) and (II): 1 or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R 1 is hydrogen or halo; R 2 and R 3 are independently hydrogen or C 1-6 alkyl; R 4 and R 5 are independently hydrogen or C 1-6 alkyl; R 6 is hydrogen, C 1-12 alkyl, C 1-6 alkoxy (C 1-6 )alkyl or C 1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C 3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R 7 and R 8 are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R 9 is C 1-6 alkyl or C 3-8 cycloalkyl; R 10 is C 1-6 alkyl or NR 11 R 12 ; L is (CR 11 R 12 ) n or NR 11 ; M is NR 11 or (CR 11 R 12 ) n ; R 11 and R 12 are independently hydrogen or C 1-6 alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C 1-6 alkyl; with the proviso that when R 9 is C 1-6 alkyl, L is not NR 11 . These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了式(I)和(II)的化合物：1或其药学上可接受的酯和药学上可接受的盐：其中，R1是氢或卤素；R2和R3分别是氢或C1-6烷基；R4和R5分别是氢或C1-6烷基；R6是氢、C1-12烷基、C1-6烷氧基(C1-6)烷基或C1-12烷基，其被选自C3-8环烷基、芳基、杂芳基和杂环的最多3个取代基取代；R7和R8是氢或一起形成具有一个或两个碳原子的烷基链；R9是C1-6烷基或C3-8环烷基；R10是C1-6烷基或NR11R12；L是(CR11R12)或NR11；M是NR11或(CR11R12)n；R11和R12分别是氢或C1-6烷基；n是0到5的整数；m是0到2的整数；所述的杂环、芳基和杂芳基未取代或被至少一个取代基所取代，所述取代基被选自卤素和C1-6烷基；但当R9是C1-6烷基时，L不是NR11。这些化合物具有5-HT4受体结合活性，因此在哺乳动物，尤其是人类的治疗胃食管反流病、非溃疡性消化不良、肠易激综合征等方面是有用的。本发明还提供了包含上述化合物的制药组合物。
• US6979690B2
  申请人：——

  公开号：US6979690B2

  公开（公告）日：2005-12-27
• [EN] OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES OXO OU OXY-PYRIDINE UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2003057688A2

  公开（公告）日：2003-07-17

  This invention provides compounds of the formula (I) and (II) or the phannaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R?2 and R3¿ are independently hydrogen or C¿1-6? alkyl; R?4 and R5¿ are independently hydrogen or C¿1-6? alkyl; R?6¿ is hydrogen, C ¿l-12? alkyl, C 1-6 alkoxy (C1-6)alkyl or C1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R?7 and R8¿ are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R9 is C¿1-6? alkyl or C3-8 cycloalkyl; R?10¿ is C¿1-6? alkyl or NR?11R12¿; L is (CR11R12)n or NR11 ; M is NR?11 or (CR11R12)n ; R11 and R12¿ are independently hydrogen or C¿1-6? alkyl; n is an integer from 0 to 5; and. m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C1-6 alkyl; with the proviso that when R?9¿ is C¿1-6? alkyl, L is not NR?11¿. These compounds have 5-HT¿4? receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.